Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Sulfotransferase 1A1 genotype as a potential modifier of breast cancer risk among premenopausal women.

Sillanpää P, Kataja V, Eskelinen M, Kosma VM, Uusitupa M, Vainio H, Mitrunen K, Hirvonen A.

Pharmacogenet Genomics. 2005 Oct;15(10):749-52.

PMID:
16141802
2.

NAT2 slow acetylator genotype as an important modifier of breast cancer risk.

Sillanpää P, Hirvonen A, Kataja V, Eskelinen M, Kosma VM, Uusitupa M, Vainio H, Mitrunen K.

Int J Cancer. 2005 Apr 20;114(4):579-84.

3.

Vitamin D receptor gene polymorphism as an important modifier of positive family history related breast cancer risk.

Sillanpää P, Hirvonen A, Kataja V, Eskelinen M, Kosma VM, Uusitupa M, Vainio H, Mitrunen K.

Pharmacogenetics. 2004 Apr;14(4):239-45.

PMID:
15083068
4.
5.

Genetic polymorphisms of glutathione S-transferases as modulators of lung cancer susceptibility.

Stücker I, Hirvonen A, de Waziers I, Cabelguenne A, Mitrunen K, Cénée S, Koum-Besson E, Hémon D, Beaune P, Loriot MA.

Carcinogenesis. 2002 Sep;23(9):1475-81.

PMID:
12189190
6.

Combined COMT and GST genotypes and hormone replacement therapy associated breast cancer risk.

Mitrunen K, Kataja V, Eskelinen M, Kosma VM, Kang D, Benhamou S, Vainio H, Uusitupa M, Hirvonen A.

Pharmacogenetics. 2002 Jan;12(1):67-72.

PMID:
11773866
7.

Polymorphic catechol-O-methyltransferase gene and breast cancer risk.

Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S, Kang D, Vainio H, Uusitupa M, Hirvonen A.

Cancer Epidemiol Biomarkers Prev. 2001 Jun;10(6):635-40.

8.

Association between manganese superoxide dismutase (MnSOD) gene polymorphism and breast cancer risk.

Mitrunen K, Sillanpää P, Kataja V, Eskelinen M, Kosma VM, Benhamou S, Uusitupa M, Hirvonen A.

Carcinogenesis. 2001 May;22(5):827-9.

PMID:
11323405
9.

Glutathione S-transferase M1, M3, P1, and T1 genetic polymorphisms and susceptibility to breast cancer.

Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S, Vainio H, Uusitupa M, Hirvonen A.

Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):229-36.

10.

Steroid metabolism gene CYP17 polymorphism and the development of breast cancer.

Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S, Vainio H, Uusitupa M, Hirvonen A.

Cancer Epidemiol Biomarkers Prev. 2000 Dec;9(12):1343-8.

11.

Role of arylamine N-acetyltransferase 1 and 2 (NAT1 and NAT2) genotypes in susceptibility to oral/pharyngeal and laryngeal cancers.

Jourenkova-Mironova N, Wikman H, Bouchardy C, Mitrunen K, Dayer P, Benhamou S, Hirvonen A.

Pharmacogenetics. 1999 Aug;9(4):533-7. No abstract available.

PMID:
10780274
12.

High-activity microsomal epoxide hydrolase genotypes and the risk of oral, pharynx, and larynx cancers.

Jourenkova-Mironova N, Mitrunen K, Bouchardy C, Dayer P, Benhamou S, Hirvonen A.

Cancer Res. 2000 Feb 1;60(3):534-6.

13.

N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk.

Bouchardy C, Mitrunen K, Wikman H, Husgafvel-Pursiainen K, Dayer P, Benhamou S, Hirvonen A.

Pharmacogenetics. 1998 Aug;8(4):291-8.

PMID:
9731715
14.

One-step all-in-one dry reagent immunoassays with fluorescent europium chelate label and time-resolved fluorometry.

Lövgren T, Meriö L, Mitrunen K, Mäkinen ML, Mäkelä M, Blomberg K, Palenius T, Pettersson K.

Clin Chem. 1996 Aug;42(8 Pt 1):1196-201.

15.

Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum.

Mitrunen K, Pettersson K, Piironen T, Björk T, Lilja H, Lövgren T.

Clin Chem. 1995 Aug;41(8 Pt 1):1115-20.

Supplemental Content

Loading ...
Support Center